Jenburkt Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
JENBURPH
Pharmaceuticals
Screen Jenburkt Pharmaceuticals share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹1115.80
▼
-18.75 (-1.65%)
Market Cap
₹480.20 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
2.63
EPS (TTM)
₹72.65
Dividend Yield
1.65%
Debt to Equity
0.01
52W High
₹1392.65
52W Low
₹938.05
Operating Margin
26.00%
Profit Margin
19.76%
Revenue (TTM)
₹167.00
EBITDA
₹49.00
Net Income
₹33.00
Total Assets
₹196.00
Total Equity
₹172.00
Jenburkt Pharmaceuticals Share Price History - Stock Screener Chart
Screen JENBURPH historical share price movements with interactive charts. Analyze price trends and patterns.
Jenburkt Pharmaceuticals Company Profile - Fundamental Screener
Screen Jenburkt Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for JENBURPH shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE354A01013
Jenburkt Pharmaceuticals Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen JENBURPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 196 | 165 | 142 | 143 | 121 | 104 | 103 | 78 | 76 | 58 |
| Current Assets | 57 | 110 | 81 | 76 | 80 | 90 | 90 | 66 | 64 | 45 |
| Fixed Assets | 15 | 10 | 10 | 11 | 11 | 12 | 10 | 10 | 11 | 12 |
| Liabilities | ||||||||||
| Total Liabilities | 196 | 165 | 142 | 143 | 121 | 104 | 103 | 78 | 76 | 58 |
| Current Liabilities | 6 | 4 | 4 | 4 | 5 | 5 | 3 | 3 | 4 | 4 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 172 | 145 | 122 | 117 | 99 | 80 | 78 | 61 | 54 | 40 |
| Share Capital | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 167 | 141 | 118 | 113 | 94 | 75 | 73 | 57 | 50 | 36 |
Screen JENBURPH income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 167 | 158 | 147 | 142 | 129 | 114 | 123 | 126 | 118 | 106 | 96 | 87 |
| Expenses | 117 | 111 | 109 | 106 | 97 | 90 | 99 | 98 | 91 | 84 | 77 | 70 |
| EBITDA | 49 | 47 | 38 | 36 | 32 | 24 | 24 | 28 | 27 | 23 | 19 | 17 |
| Operating Profit % | 26.00% | 27.00% | 23.00% | 22.00% | 22.00% | 18.00% | 17.00% | 20.00% | 21.00% | 19.00% | 18.00% | 18.00% |
| Depreciation | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 3 |
| Interest | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 46 | 44 | 35 | 33 | 30 | 22 | 21 | 27 | 25 | 21 | 17 | 14 |
| Tax | 13 | 12 | 9 | 8 | 8 | 5 | 6 | 7 | 8 | 7 | 6 | 5 |
| Net Profit | 33 | 32 | 26 | 25 | 22 | 17 | 15 | 20 | 17 | 14 | 11 | 10 |
| EPS | 74.80 | 72.65 | 58.86 | 53.90 | 48.58 | 35.96 | 32.40 | 43.14 | 37.50 | 29.05 | 23.18 | 20.75 |
Jenburkt Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen JENBURPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 28 | 8 | 17 | 9 | 20 | 15 | 13 | 16 | 10 | 8 |
| Investing Activities | -17 | -1 | 3 | -1 | -19 | -3 | -11 | 1 | -10 | 0 |
| Financing Activities | -8 | -7 | -21 | -6 | -1 | -11 | -2 | -18 | 1 | -5 |
| Net Cash Flow | 3 | 1 | -1 | 3 | 0 | 1 | 0 | -1 | 1 | 2 |
Screen JENBURPH shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 46.68% | 46.67% | 46.66% | 47.23% | 46.71% | 46.71% | 46.69% | 47.56% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.12% | 0.12% | 0.12% | 0.00% | 0.00% | 0.00% | 0.12% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 43.55% | 43.32% | 43.26% | 42.65% | 43.39% | 43.56% | 43.43% | 40.37% |
| Other Holding | 9.66% | 9.89% | 9.97% | 10.11% | 9.90% | 9.73% | 9.76% | 12.08% |
| Shareholder Count | 6,987 | 6,712 | 6,855 | 6,316 | 6,419 | 6,628 | 6,901 | 5,611 |
Jenburkt Pharmaceuticals Dividend Screener - Share Yield Analysis
Screen JENBURPH dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2025-March | ₹18.00 | 1.65% |
| 2024-March | ₹15.30 | 1.51% |
| 2023-March | ₹14.40 | 2.09% |
| 2022-March | ₹12.00 | 1.82% |
| 2021-March | ₹10.20 | 1.80% |
| 2020-March | ₹8.10 | 2.03% |
| 2019-March | ₹10.20 | 3.21% |
| 2018-March | ₹9.00 | 1.78% |
| 2017-March | ₹8.10 | 1.32% |
| 2016-March | ₹0.00 | 0.00% |
Jenburkt Pharmaceuticals Index Membership - Market Screener Classification
Screen JENBURPH by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Jenburkt Pharmaceuticals Market Events Screener - Corporate Actions
Screen JENBURPH market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-10-28 | 2025-10-28 | Quarterly Result Announcement | NA | 0.91% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -9.73% |
| 2025-07-18 | 2025-07-18 | Annual General Meeting | NA | 18.69% |
| 2025-07-11 | 2025-07-11 | Dividend | ₹ 18.00 /share | 25.87% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 9.69% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -6.60% |
| 2024-11-05 | 2024-11-05 | Quarterly Result Announcement | NA | 7.15% |
| 2024-07-30 | 2024-07-30 | Annual General Meeting | NA | 16.63% |
| 2024-07-23 | 2024-07-24 | Dividend | ₹ 15.30 /share | 8.04% |
| 2023-07-19 | 2023-07-20 | Dividend | ₹ 14.40 /share | 3.72% |
| 2022-07-21 | 2022-07-23 | Dividend | ₹ 12.00 /share | -7.44% |
| 2021-08-30 | Dividend | ₹ 10.20 /share | -9.37% |
Jenburkt Pharmaceuticals Competitors Screener - Peer Comparison
Screen JENBURPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 413,669 | 39.35 | 54,729 | 9.71% | 10,980 | 39.06 |
| Divis Laboratories | 170,922 | 68.64 | 9,712 | 18.67% | 2,191 | 44.96 |
| Torrent Pharmaceuticals | 128,481 | 60.42 | 11,539 | 6.99% | 1,911 | 59.35 |
| Cipla | 120,520 | 22.17 | 28,410 | 7.12% | 5,291 | 42.76 |
| Dr Reddys Laboratories | 105,372 | 18.42 | 33,741 | 16.73% | 5,725 | 49.97 |
| Lupin | 95,763 | 21.87 | 22,910 | 13.74% | 3,306 | 50.10 |
| Zydus Life Science | 91,094 | 18.03 | 23,511 | 18.55% | 4,615 | 34.06 |
| Mankind Pharma | 89,550 | 50.11 | 12,744 | 20.90% | 2,007 | 40.67 |
| Aurobindo Pharma | 69,034 | 20.16 | 32,346 | 9.43% | 3,484 | 46.33 |
| Alkem Laboratories | 65,175 | 26.89 | 13,458 | 3.70% | 2,216 | 37.45 |
Jenburkt Pharmaceuticals Company Announcements - News Screener
Screen JENBURPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-15 | Closure of Trading Window | View |
| 2025-10-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-28 | Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2025. | View |
| 2025-10-28 | Board Meeting Outcome for Outcome Of The Board Meeting Held Today On 28Th October 2025. | View |
| 2025-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-03 | Board Meeting Intimation for Considering And Approving Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2025. | View |
| 2025-09-22 | Closure of Trading Window | View |
| 2025-08-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-12 | Standalone Unaudited Financial Results For The Quarter Ended On 30Th June 2025. | View |
| 2025-08-12 | Board Meeting Outcome for Outcome Of The Board Meeting Held Today On 12Th August 2025. | View |
| 2025-08-01 | Board Meeting Intimation for Considering And Approving Standalone Unaudited Financial Results For The Quarter Ended On 30Th June 2025. | View |
| 2025-07-18 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-07-18 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-07-18 | Proceedings Of The 40Th Annual General Meeting Of The Company Held On Today I.E. 18Th July 2025. | View |
| 2025-07-18 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-07-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-06-23 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-06-20 | Intimation Of Record Date And Cut-Off Date | View |
| 2025-06-20 | Notice Of The 40Th Annual General Meeting Of The Company Schedule To Be Held On Friday 18Th July 2025 Through VC/OAVM. | View |
| 2025-06-20 | Reg. 34 (1) Annual Report. | View |